Navigation Links
Does the MS Market Need Another Interferon? Neurologists Provide Insight in the Wave One Report of LaunchTrends: EXTAVIA
Date:1/11/2010

EXTON, Pa., Jan. 11 /PRNewswire/ -- BioTrends Research Group, Inc. announces the release of the Wave One LaunchTrends(®): EXTAVIA report. The survey was completed by U.S. Neurologists (n=76) in November and December 2009, approximately one month following the launch of Novartis' Extavia (Interferon beta 1b).

Awareness of Extavia is relatively high but familiarity is more moderate. Over one-third of current Extavia users indicate this newest agent will be a likely replacement for Betaseron (interferon beta-1b) manufactured by Bayer, which was the first disease modifying agent approved nearly 20 years ago. Despite the relatively high awareness of Extavia, the projected uptake of Extavia appears to be modest with about half of the Neurologists expecting to prescribe Extavia within the next six months. The main advantages clinicians perceive with Extavia is the every other day dosing regimen and similarity to other interferon agents. On the downside, Extavia is viewed as yet another addition to an already crowded market with a similar mechanism of action and a lack of any clear clinical differentiation. According to one research participant, "Extavia is overshadowed by other new products. It's hard to get a real sense of excitement." Concern was also expressed that the treatment may not be priced sufficiently less expensive than existing agents to encourage its use, despite the fact that the pricing advantage was one of the most frequently recalled sales representative messages about the product.

Currently approved products include Biogen Idec's AVONEX and TYSABRI; Teva's COPAXONE and EMD Serono's REBIF. In an attribute analysis, surveyed Neurologists rated Copaxone as the top performing agent on nine out of ten of the most important attributes. There are also a number of agents in late stage clinical development for MS. There is a high degree of interest in the oral agents currently in development among which interest was highest for Novartis' own fingolimod, an oral sphingosine-1 modulator and EMD Serono's oral cladribine. EMD Serono received a refuse to file letter from the FDA dated November 30(th) and is currently working with the FDA toward a possible resubmission.

LaunchTrends (®) measure launch effectiveness of new products from FDA approval through six months post launch. The next wave of this report, measuring uptake at three months post launch, will be fielded on February 15th with the results to be published on February 28, 2010.

As part of BioTrends continuing commitment to the MS market we are pleased to announce the continuation of the TreatmentTrends(®): Multiple Sclerosis Report in 2010. This second report in an on-going series will cover U.S. market trends including key product use (current and future) across the different clinical manifestations of MS, disease awareness and attitudes, importance of product attributes for disease modifying therapies and brand performance against those attributes, and awareness of products in late stage development. This report is scheduled to field at the end of January and will be published in mid-February.

About BioTrends Research Group, Inc.

BioTrends Research Group, Inc. (www.bio-trends.com) provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. To purchase this report or to learn more about BioTrends' syndicated publications, please contact Paul Callahan at (610) 363-3872 or visit us at www.bio-trends.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.

SOURCE BioTrends Research Group, Inc.

RELATED LINKS
http://www.bio-trends.com

'/>"/>

SOURCE BioTrends Research Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
2. FDA Advisory Committees Recommend Continued U.S. Marketing Authorization for Trasylol(R)
3. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
4. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
5. Results of TRIUMPH-1 Trial of Viveta in Pulmonary Arterial Hypertension to Be Announced Before Market Open on Thursday, November 1, 2007
6. Inverness Medical Innovations to Present at CIBC World Markets 18th Annual Healthcare Conference on November 7, 2007
7. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
8. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
9. Replidyne to Participate on Anti-infective Panel at RBC Capital Markets Healthcare Conference
10. GE Healthcare and Novavax Establish Collaboration To Develop and Market Pandemic Influenza Solution
11. Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... May 26, 2016 Since its ... into an essential life science tool for conducting genetic ... BCC Research reveals in its new report that the ... phase, one powered by a range of new applications ...      (Logo: http://photos.prnewswire.com/prnh/20140723/694805 ) , ...
(Date:5/25/2016)... GERMANTOWN, Maryland , May 25, 2016 /PRNewswire/ ... Frankfurt Prime Standard: QIA) today announced that the company has ... GmbH to develop and commercialize predictive assays in oncology. An ... a marker to predict effectiveness of anthracycline treatment in triple ... are pleased to partner with Therawis, which developed the PITX2 ...
(Date:5/25/2016)... 2016 As illustrated by the ... month, the numbers and momentum of cannabis in the ... the billions, more research and development push the sector ... of Legal Marijuana Markets Report  from from ArcView Market ... of the increase in sector is attributed to adult ...
Breaking Medicine Technology:
(Date:5/28/2016)... ... ... "Color Grading media can be time consuming but with FCPX LUT Night ... Austin - CEO of Pixel Film Studios. , With the FCPX LUT Night ... to their footage. A LUT is a Lookup Table that contains a mathematical formula ...
(Date:5/27/2016)... CA (PRWEB) , ... May 27, 2016 , ... More ... Health, so it is not surprising that bariatric surgery has received increased attention in ... Journal explains. Of course, when it comes to weight loss, most people are familiar ...
(Date:5/27/2016)... ... May 27, 2016 , ... An influential resource amongst nurses and ... to shed lights on the variety of topics detailing why we appreciate nurses in ... why this career has gone from being in a major recession to one of ...
(Date:5/27/2016)... ... May 27, 2016 , ... ... educate the many who are unaware of the plight of aphasia. In collaboration ... within the “Stroke Awareness” campaign. , The link between stroke and aphasia is ...
(Date:5/27/2016)... ... May 27, 2016 , ... Each year Standard ... Allison Outerbridge is this year’s Life University winner of a $2,500 ... university’s Student Leadership Awards ceremony. , Outerbridge is approaching her last quarter at ...
Breaking Medicine News(10 mins):